Zhi-Wei Guo

Zhi-Wei Guo


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
LLLi Lin
Li Lin
GCGeng-Xi Cai
Geng-Xi Cai
XZXiang-Ming Zhai
Xiang-Ming Zhai
XYXue-Xi Yang
Xue-Xi Yang
MLMin Li
Min Li
ZGZhi-Wei Guo
Zhi-Wei Guo
Breast cancer is the second cause of cancer-associated death among women and seriously endangers women’s health. Therefore, early identification of breast cancer would be beneficial to women’s health. At present, circular RNA (circRNA) not only exists in the extracellular vesicles (EVs) in plasma, but also presents distinct patterns under different physiological and pathological conditions. Therefore, we assume that circRNA could be used for early diagnosis of breast cancer. Here, we developed classifiers for breast cancer diagnosis that relied on 259 samples, including 144 breast cancer patients and 115 controls. In the discovery stage, we compared the genome-wide long RNA profiles of EVs in patients with breast cancer (n=14) and benign breast (n=6). To further verify its potential in early diagnosis of breast cancer, we prospectively collected plasma samples from 259 individuals before treatment, including 144 breast cancer patients and 115 controls. Finally, we developed and verified the predictive classifies based on their circRNA expression profiles of plasma EVs by using multiple machine learning models. By comparing their circRNA profiles, we found 439 circRNAs with significantly different levels between cancer patients and controls. Considering the cost and practicability of the test, we selected 20 candidate circRNAs with elevated levels and detected their levels by quantitative real-time polymerase chain reaction. In the training cohort, we found that BCExoC, a nine-circRNA combined classifier with SVM model, achieved the largest AUC of 0.83 [95% CI 0.77-0.88]. In the validation cohort, the predictive efficacy of the classifier achieved 0.80 [0.71-0.89]. Our work reveals the application prospect of circRNAs in plasma EVs as non-invasive liquid biopsies in the diagnosis and management of breast cancer.

10 September 2022 in BMC Pregnancy and Childbirth
Verified
Journal Article
Open access
PDF file
QLQianwen Lu
Qianwen Lu
ZGZhi-Wei Guo
Zhi-Wei Guo
JZJun Zhang
Jun Zhang
KWKe Wang
Ke Wang
QTQi Tian
Qi Tian
FYFang Yang
Fang Yang
Fetal macrosomia is common occurrence in pregnancy, which is associated with several adverse prognosis both of maternal and neonatal. While, the accuracy of prediction of fetal macrosomia is poor. The aim of this study was to develop a reliable noninvasive prediction classifier of fetal macrosomia. A total of 3600 samples of routine noninvasive prenatal testing (NIPT) data at 12+ 0–27+ 6 weeks of gestation, which were subjected to low-coverage whole-genome sequencing of maternal plasma cell-free DNA (cfDNA), were collected from three independent hospitals. We identified set of genes with significant differential coverages by comparing the promoter profiling between macrosomia cases and controls. We selected genes to develop classifier for noninvasive predicting, by using support vector machine (SVM) and logistic regression models, respectively. The performance of each classifier was evaluated by area under the curve (AUC) analysis. According to the available follow-up results, 162 fetal macrosomia pregnancies and 648 matched controls were included. A total of 1086 genes with significantly differential promoter profiling were found between pregnancies with macrosomia and controls (p < 0.05). With the AUC as a reference,the classifier based on SVM (CMA-A2) had the best performance, with an AUC of 0.8256 (95% CI: 0.7927–0.8586). Our study provides that assessing the risk of fetal macrosomia by whole-genome promoter nucleosome profiling of maternal plasma cfDNA based on low-coverage next-generation sequencing is feasible.

13 August 2025 in BMC Cancer
Verified
Journal Article
Open access
PDF file
XZXiang-Ming Zhai
Xiang-Ming Zhai
YYYi-Qi Yang
Yi-Qi Yang
LLLi Lin
Li Lin
HLHuan-Chang Luo
Huan-Chang Luo
ZGZhi-Wei Guo
Zhi-Wei Guo
YWYingsong Wu
Yingsong Wu
Gastric cancer (GC) is the fourth most common cause of cancer death and has the fifth highest incidence of cancer worldwide. Circular RNAs (circRNAs) have emerged as essential regulators of tumorigenesis and cancer progression. However, the underlying regulatory mechanisms and their roles as diagnostic biomarkers have yet to be well elucidated in GC. In this study, we implemented genome-wide sequencing to identify circRNAs whose expression in plasma extracellular vesicles (EVs) significantly changed. Functional experiments were performed to assess its effect on the proliferation, viability, migration and apoptosis of GC cell lines. Luciferase reporter and RNA pull-down assays were used to validate their combinations. Finally, RNA-Seq and RT-qPCR were used to identify the downstream regulatory pathway involved. We found that the circRNA of MORC family CW-type zinc finger 1 gene (circMORC1) was decreased in the plasma EVs of GC patients but increase in GC cells. In vivo, circMORC1 promoted proliferation, viability, and migration and inhibited apoptosis in AGS and SGC-7901 GC cell lines. CircMORC1 was found to bind to miR-103a-1-5p, which is essential for the regulation of phenotypes. In addition, the Wnt pathway was found to be the downstream regulatory pathway of circMORC1 through a miR-103a-1-5p sponge. Our results shed light on circMORC1 promotes the proliferation of gastric cancer cells, as a RNA sponge of miR-103a-1-5p and counteracted the down-regulation of Wnt signaling function of miR-103a-1-5p. Revealed a novel mechanism by which circMORC1 regulates tumorigenesis in gastric cancer and provided a new biomarker for GC diagnosis and prognosis.